Pralatrexate experience in PTCL: A multicenter retrospective study from Turkey

Area of Science:

• Oncology
• Pharmacology

Background:

• Peripheral T-cell lymphomas (PTCL) are aggressive non-Hodgkin lymphomas.
• Relapsed or refractory PTCL presents significant treatment challenges.
• Pralatrexate is a novel antifolate agent for PTCL treatment.

Purpose of the Study:

• To characterize patients receiving pralatrexate in Turkey.
• To evaluate pralatrexate's effectiveness in PTCL.
• To identify major side effects of pralatrexate therapy.

Main Methods:

• Retrospective study of 20 adult PTCL patients in Turkey.
• Patients received pralatrexate therapy.
• Data collected on patient characteristics, treatment, response, and side effects.

Main Results:

• Median age at diagnosis was 58.5 years.
• PTCL-Not Otherwise Specified (NOS) was the most common subtype (40%).
• 55% of patients achieved partial remission (PR) or better with pralatrexate.
• Dose reduction was needed in 15% of patients.

Conclusions:

• Pralatrexate is a promising treatment for relapsed/refractory PTCL.
• Close patient follow-up is crucial for managing side effects.
• Potential side effects include skin reactions, mucosal issues, thrombocytopenia, and neutropenia.